Sanofi announced 3rd quarter 2016 results on Friday, October 28th. This interview with Sanofi CFO Jérôme Contamine discusses the details of the release.
Highlights include an overall increase in sales, and a double-digit increase in growth of global business units (GBUs). The sales increase was driven by performance in the specialty GBU, Sanofi Genzyme, and the vaccine GBU, Sanofi Pasteur.
He also discusses the progress of Sanofi's current cost-savings program, as well as issues with diabetes drug pricing in the US, and how this will affect future earnings.